Correlation Between NextCure and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both NextCure and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NextCure and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NextCure and SAB Biotherapeutics, you can compare the effects of market volatilities on NextCure and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NextCure with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NextCure and SAB Biotherapeutics.

Diversification Opportunities for NextCure and SAB Biotherapeutics

0.51

Correlation Coefficient

NextCure  SAB Biotherapeutics

Very weak diversification

The 3 months correlation between NextCure and SAB is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding NextCure and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and NextCure is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NextCure are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of NextCure i.e., NextCure and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between NextCure and SAB Biotherapeutics

Given the investment horizon of 90 days NextCure is expected to under-perform the SAB Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, NextCure is 1.45 times less risky than SAB Biotherapeutics. The stock trades about -0.03 of its potential returns per unit of risk. The SAB Biotherapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  980.00  in SAB Biotherapeutics on February 19, 2025 and sell it today you would lose (800.00) from holding SAB Biotherapeutics or give up 81.63% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

NextCure  vs.  SAB Biotherapeutics

NextCure

Risk-Adjusted Performance

Very Weak

Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in June 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, SAB Biotherapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with NextCure and SAB Biotherapeutics

The main advantage of trading using opposite NextCure and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NextCure position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind NextCure and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.